<h4>Introduction</h4>Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are therapies for type 2 diabetes whose use expanded sharply after semaglutide's 2021 approval for obesity. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.